
Verastem Oncology's VSTM.O shares rise 4.8% to $7.86 in early trading
Cancer drug developer announces $75 million private placement led by investment firm RTW
Firm has agreed with investors for placement of $24 million of shares and $51 million of pre-funded warrants
Guggenheim Securities was the lead agent for the private placement
Proceeds will be used to fund the potential launch of its experimental cancer therapy avutometinib and other purposes
As of last close, VSTM stock up 45% YTD